Detalhe da pesquisa
1.
Construction of immune cell infiltration score model to assess prognostic ability of tumor immune environment in lung adenocarcinoma.
Am J Transl Res
; 15(3): 1730-1743, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37056847
2.
Identification of novel, potent and selective inhibitors of Polo-like kinase 1.
Bioorg Med Chem Lett
; 22(2): 1247-50, 2012 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22172702
3.
Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor.
Eur J Pharm Sci
; 136: 104938, 2019 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31132401
4.
Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification.
Oncotarget
; 8(31): 50832-50844, 2017 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28881608
5.
Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation.
Oncotarget
; 7(36): 57651-57670, 2016 Sep 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27472392
6.
Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models.
Mol Oncol
; 9(1): 323-33, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25248999
7.
Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer.
J Med Chem
; 57(18): 7577-89, 2014 Sep 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-25148209
8.
Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.
Cancer Biol Ther
; 15(12): 1635-45, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25482937
9.
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
Proc Natl Acad Sci U S A
; 103(6): 1888-93, 2006 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-16443686
10.
A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.
Cancer Res
; 66(17): 8731-9, 2006 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16951189